Biologics Standards for Innovation, Quality and Access
This GEN Spotlight on Biologics Standards for Innovation, Quality and Access brings together experts from across biopharma, standards development, and analytical science to examine the challenges of testing increasingly complex modalities, including monoclonal antibodies, cell and gene therapies, and RNA therapeutics. The post Biologics Standards for Innovation, Quality and Access appeared first…
Panelists from the "Biologics Standards for Innovation, Quality and Access" registration event shared their expertise in quality assurance, analytical sciences and quality control. Erin Dieveney, Vice President of Quality Assurance at Aldevron, emphasized the importance of maintaining product quality, compliance and reliability for next-generation genomic medicines.
Khaled Yamout, Founder and CEO of Y-Chem Consulting, highlighted his extensive experience in analytical sciences, quality and manufacturing, having previously held senior director positions at TriLink Biotechnologies. Yamout stressed the need for robust analytical methods, validation and regulatory compliance in the development and release of both small and large molecules.
Kok-Seong Lim, PhD, Founder and Principal of Eight Crest Strategies, brought his insights as a thought leader in the field, without specifying his exact role or responsibilities.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
